Tower Research Capital (TRC)’s Novavax NVAX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $205K | Buy |
25,210
+22,033
| +694% | +$200K | 0.01% | 1599 |
|
|
2025
Q4 | $21.4K | Sell |
3,177
-7,419
| -70% | -$55.9K | ﹤0.01% | 3056 |
|
|
2025
Q3 | $91.9K | Sell |
10,596
-26,739
| -72% | -$208K | ﹤0.01% | 2059 |
|
|
2025
Q2 | $235K | Buy |
37,335
+30,386
| +437% | +$201K | 0.01% | 1630 |
|
|
2025
Q1 | $44.9K | Sell |
6,949
-22,441
| -76% | -$186K | ﹤0.01% | 2296 |
|
|
2024
Q4 | $236K | Buy |
29,390
+11,632
| +66% | +$112K | ﹤0.01% | 1605 |
|
|
2024
Q3 | $224K | Sell |
17,758
-43,436
| -71% | -$561K | 0.01% | 1528 |
|
|
2024
Q2 | $775K | Buy |
61,194
+59,563
| +3,652% | +$599K | 0.01% | 966 |
|
|
2024
Q1 | $7.8K | Sell |
1,631
-12,313
| -88% | -$57.1K | ﹤0.01% | 4135 |
|
|
2023
Q4 | $66.9K | Buy |
13,944
+7,072
| +103% | +$43.3K | ﹤0.01% | 2938 |
|
|
2023
Q3 | $49.8K | Sell |
6,872
-25,143
| -79% | -$201K | ﹤0.01% | 2554 |
|
|
2023
Q2 | $238K | Buy |
32,015
+15,070
| +89% | +$119K | 0.01% | 1432 |
|
|
2023
Q1 | $118K | Sell |
16,945
-12,726
| -43% | -$117K | ﹤0.01% | 1710 |
|
|
2022
Q4 | $305K | Sell |
29,671
-2,258
| -7% | -$39.8K | 0.01% | 1001 |
|
|
2022
Q3 | $581K | Buy |
31,929
+5,234
| +20% | +$227K | 0.01% | 1026 |
|
|
2022
Q2 | $1.37M | Buy |
26,695
+19,803
| +287% | +$1.03M | 0.03% | 527 |
|
|
2022
Q1 | $507K | Buy |
6,892
+4,014
| +139% | +$358K | ﹤0.01% | 1141 |
|
|
2021
Q4 | $412K | Buy |
2,878
+501
| +21% | +$86.1K | 0.01% | 1242 |
|
|
2021
Q3 | $493K | Buy |
2,377
+891
| +60% | +$196K | 0.01% | 1000 |
|
|
2021
Q2 | $316K | Sell |
1,486
-4,426
| -75% | -$811K | 0.01% | 1563 |
|
|
2021
Q1 | $1.07M | Sell |
5,912
-1,272
| -18% | -$253K | 0.02% | 750 |
|
|
2020
Q4 | $801K | Buy |
7,184
+5,089
| +243% | +$541K | 0.02% | 639 |
|
|
2020
Q3 | $227K | Sell |
2,095
-9,442
| -82% | -$1.15M | ﹤0.01% | 2457 |
|
|
2020
Q2 | $962K | Buy |
+11,537
| New | +$441K | 0.04% | 553 |
|
|
2020
Q1 | – | Sell |
-2,123
| Closed | -$9K | – | 3627 |
|
|
2019
Q4 | $9K | Sell |
2,123
-5,043
| -70% | -$21.9K | ﹤0.01% | 2394 |
|
|
2019
Q3 | $36K | Buy |
7,166
+5,917
| +474% | +$32.4K | ﹤0.01% | 2027 |
|
|
2019
Q2 | $7K | Sell |
1,249
-1,934
| -61% | -$15.2K | ﹤0.01% | 2776 |
|
|
2019
Q1 | $35K | Buy |
3,183
+3,168
| +21,120% | +$100K | ﹤0.01% | 1950 |
|
|
2018
Q4 | $1K | Sell |
15
-730
| -98% | -$28.3K | ﹤0.01% | 3631 |
|
|
2018
Q3 | $28K | Sell |
745
-123
| -14% | -$3.46K | ﹤0.01% | 2125 |
|
|
2018
Q2 | $23K | Buy |
868
+519
| +149% | +$17.5K | ﹤0.01% | 2357 |
|
|
2018
Q1 | $15K | Sell |
349
-297
| -46% | -$11.9K | ﹤0.01% | 2305 |
|
|
2017
Q4 | $16K | Buy |
+646
| New | +$15.8K | ﹤0.01% | 2235 |
|
|
2017
Q2 | – | Sell |
-85
| Closed | -$2K | – | 3211 |
|
|
2017
Q1 | $2K | Buy |
85
+60
| +240% | +$1.65K | ﹤0.01% | 2648 |
|
|
2016
Q4 | $1K | Buy |
+25
| New | +$729 | ﹤0.01% | 3632 |
|
|
2016
Q2 | – | Sell |
-74
| Closed | -$8K | – | 4805 |
|
|
2016
Q1 | $8K | Buy |
+74
| New | +$7.94K | ﹤0.01% | 2224 |
|
|
2015
Q4 | – | Sell |
-23
| Closed | -$3K | – | 4877 |
|
|
2015
Q3 | $3K | Sell |
23
-273
| -92% | -$61.2K | ﹤0.01% | 3147 |
|
|
2015
Q2 | $66K | Sell |
296
-573
| -66% | -$101K | 0.01% | 1152 |
|
|
2015
Q1 | $144K | Buy |
869
+814
| +1,480% | +$132K | 0.02% | 608 |
|
|
2014
Q4 | $7K | Sell |
55
-748
| -93% | -$78.2K | ﹤0.01% | 2454 |
|
|
2014
Q3 | $67K | Buy |
803
+763
| +1,908% | +$69K | 0.01% | 1295 |
|
|
2014
Q2 | $4K | Sell |
40
-115
| -74% | -$10.1K | ﹤0.01% | 3010 |
|
|
2014
Q1 | $14K | Buy |
+155
| New | +$17.3K | ﹤0.01% | 2260 |
|
|
2013
Q4 | – | Sell |
-2,864
| Closed | -$180K | – | 4785 |
|
|
2013
Q3 | $180K | Buy |
+2,864
| New | +$161K | 0.02% | 821 |
|
Other funds holding NVAX
SCM
VPM
VCM
S
Tower Research Capital (TRC)'s NVAX Position: Q1 2026 in Review
Tower Research Capital (TRC) increased its Novavax (NVAX) stake by 694% in Q1 2026, buying an estimated $200K and bringing the position to 25,210 shares worth $205K. The position accounts for 0.01% of the portfolio, ranked #1599.
Tower Research Capital (TRC) first reported a position in NVAX in Q3 2013 and has held it in 44 quarters since. The position peaked at $1.37M in Q2 2022. 258 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.
- Tower Research Capital (TRC) held 25,210 shares of Novavax worth $205K as of Q1 2026.
- Tower Research Capital (TRC) bought 22,033 Novavax shares in Q1 2026, an estimated $200K.
- Novavax made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #1599 holding.
- Tower Research Capital (TRC) first reported a position in Novavax in Q3 2013 and has held it in 44 quarters since.
- Tower Research Capital (TRC)'s Novavax position peaked at $1.37M in Q2 2022.
- 258 funds tracked by Wall St. Rank held Novavax as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.